Bone Loss
Bone drugs may not protect osteoporotic women from breast cancer
August 25, 2014Osteoporosis drugs known as bisphosphonates may not protect women from breast cancer as had been thought, according to a new study.
Guidance to prevent fractures in cancer-associated bone disease
November 19, 2013The epidemiology and pathophysiology of cancer-associated bone disease was reviewed in a new paper published by an International Osteoporosis Foundation (IOF) Committee of Scientific Advisors Working Group.
Calcium/vitamin D don't stop bone loss in breast cancer
September 24, 2013A review of calcium and vitamin D supplementation trials revealed that current recommended doses are inadequate to prevent bone mineral density loss in women undergoing breast cancer therapy.
A roundup of FDA news from June 2013
July 05, 2013FDA-related news items of relevance from the month of June, 2013.
Burden of giant-cell tumor of the bone reduced by denosumab
September 27, 2012When patients with giant-cell tumor of the bone were treated with denosumab, which is a drug targeted against a protein that promotes bone destruction, the number of tumor giant cells decreased and new bone formation increased.
Calcium and vitamin D may hurt, not help, in prostate cancer
August 28, 2012Calcium and/or vitamin D supplementation at commonly recommended doses does not prevent bone loss from androgen-deprivation therapy.
Denosumab Better for Breast Cancer With Bone Metastases
August 16, 2012Denosumab better prevents skeletal complications, ups health-related QoL versus zoledronic acid.
Gum disease may affect HPV status of head-and-neck tumors
July 12, 2012A history of periodontitis may be associated with an increased risk of HPV-positive tumors in persons with head and neck squamous cell carcinoma.
BMD loss occurs early in androgen deprivation therapy
April 12, 2012Study finds loss evident in men treated with ADT for nonmetastatic, hormone-sensitive prostate cancer.
Bone loss risk highlighted
January 26, 2010The risk of bone loss resulting from breast and prostate cancer treatment has been highlighted by researchers in Canada.
ONA Articles
- Sexual Dysfunction in Women With Cancer: A Review of Available Interventions
- Osteoporosis Medication Improves Bone Health in ADT-Treated Prostate Cancer
- Inotuzumab Ozogamicin Granted FDA Approval for Acute Lymphoblastic Leukemia
- Value of Type and Crossmatch Prior to Daratumumab Administration
- Cabazitaxel in Prostate Cancer: Reduced Dose Noninferior to Standard Dose
- To Better Serve Patients With Cancer, Navigators Need Better Systems
- Physical Activity Improves Cognitive Function for Breast Cancer Survivors
- Risk of Lung Cancer Increases With Diets Higher in Saturated Fats
- Mechanisms Identified for Curcumin Resensitization of Cancer Cells
- Value of Type and Crossmatch Prior to Daratumumab Administration
- Arthritis Medication Shows Potential in the Treatment of Polycythemia Vera
- Inotuzumab Ozogamicin Granted FDA Approval for Acute Lymphoblastic Leukemia
- Osteoporosis Medication Improves Bone Health in ADT-Treated Prostate Cancer
- Breast Conservation Improves Survival vs Mastectomy in Breast Cancer
- Cabazitaxel in Prostate Cancer: Reduced Dose Noninferior to Standard Dose
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
| Bone Cancer | Regimens | Drugs |
| Brain Cancer | Regimens | Drugs |
| Breast Cancer | Regimens | Drugs |
| Endocrine Cancer | Regimens | Drugs |
| Gastrointestinal Cancer | Regimens | Drugs |
| Genitourinary Cancer | Regimens | Drugs |
| Gynecologic Cancer | Regimens | Drugs |
| Head and Neck Cancer | Regimens | Drugs |
| Hematologic Cancer | Regimens | Drugs |
| Lung Cancer | Regimens | Drugs |
| Other Cancers | Regimens | |
| Rare Cancers | Regimens | |
| Skin Cancer | Regimens | Drugs |